Clinical trials: Diabetic Glomerulosclerosis
- Condition Diabetic Glomerulosclerosis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
The study will comprise primarily a single-ascending dose (SAD) escalation component.
- Trial name
- NCT03970122
- Testing
- GFB-887
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.